Day One Reports First Quarter 2025 Financial Results and Corporate Progress
Provided By GlobeNewswire
Last update: May 6, 2025
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024
Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million
Read more at globenewswire.com
